Juul to cut 30% of its workforce in bid to cut costs and boost profitability

Juul to cut 30% of its workforce in bid to cut costs and boost profitability


Juul Labs signage is seen in the window of a store in San Francisco, June 25, 2019.

David Paul Morris | Bloomberg | Getty Images

Juul Labs said Wednesday it’s planning to cut about 30% of its workforce as it looks to cut costs and boost profits.

The layoffs will affect roughly 250 people, reducing the company’s headcount to about 650, a company spokesperson said.

This will reduce operating expenses by $225 million, the Juul spokesperson added.

Juul – which is seeking federal authorization to keep its e-cigarette products on the market – said the cuts will improve its margins and free up cash for litigation settlements.

“Today, Juul Labs is announcing a company restructuring aimed at reducing our operating costs and positioning us to continue to advance our mission during a period of regulatory and marketplace uncertainty,” the company said in a news release.

Last year, the vaping giant had its products ordered off the market by the Food and Drug Administration. Juul appealed the decision and the ban was reversed for the time being.

The company later secured enough financing from early investors to avoid bankruptcy. It also announced plans at the time to lay off nearly a third of staff.

Since then, Juul has been trying to raise more capital from investors as it awaits a decision from U.S. regulators on whether its current products can remain on the market, a company spokesperson said.

The company’s also been embroiled in costly legal battles, paying over $1 billion worth of settlements to 45 states for its role in sparking a national surge in teen vaping.

Earlier this week, Juul was sued by Marlboro maker Altria Group, which previously held significant stake in Juul, for alleged patent infringement over certain e-vapor products owned by subsidiary NJOY.

In response to the suit, a Juul spokesperson told CNBC, “We stand behind our intellectual property and will continue to pursue our infringement claims.”



Source

How we’re thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
Health

How we’re thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS

Enthusiasm for Club holding Eli Lilly needs to be tempered — at least for now — as Wall Street grapples with the possibility of a major shakeup to health policy in Washington. The news Republican President-elect Donald Trump on Thursday nominated prominent vaccine skeptic and obesity-drug critic Robert F. Kennedy Jr. to lead the Department […]

Read More
Jim Cramer’s top 10 things to watch in the stock market Friday
Health

Jim Cramer’s top 10 things to watch in the stock market Friday

My top 10 things to watch Friday, Nov. 15 1. President-elect Donald Trump’s decision to nominate prominent vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services has vast implications for drug companies. That’s why shares of pharma stocks, and vaccine makers in particular, sold off late Thursday when reports […]

Read More
Here’s a rapid-fire update on what Trump will mean for all 33 portfolio stocks
Health

Here’s a rapid-fire update on what Trump will mean for all 33 portfolio stocks

Here’s a rapid-fire update on all the stocks in Jim Cramer’s Charitable Trust, the portfolio we use for the CNBC Investing Club. During the November Monthly Meeting on Thursday, Jim looked at how Donald Trump’s return to the White House could impact each company — good, bad or not much at all. Apple : If […]

Read More